Skip to main content
SpringerLink
Log in

Pathogenesis and Management of Cancer-Associated Hypercalcaemia

  • Chapter
Bone Metastases

Abstract

Hypercalcaemia is the most common metabolic complication of malignant disease, occurring in about 5%–10% of cancer patients overall (Fisken et al. 1980). Although hypercalcaemia can occur with virtually any tumour, some cancers cause hypercalcaemia more frequently than others: squamous cancers and uro-epithelial cancers, for example, are common causes of hypercalcaemia, as are breast cancers and myeloma. Conversely, adenocarcinomas of the intestine seldom cause hypercalcaemia (Mundy and Martin 1982). These differences are interesting in that they reflect the ability of some tumours to release humoral factors which cause hypercalcaemia by their effects at regulatory sites of calcium homeostasis in bone, intestine and kidney.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adami S, Bolzicci GP, Rizzo A et al. (1987) The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcaemia of malignancy. Bone Miner 2:395–404

    PubMed  CAS  Google Scholar 

  • Anggard E, Samuelsson B (1964). Metabolism of prostaglandin El in the guinea pig lung: The structure of two metabolites. J Biol Chem 239:4097–4102

    CAS  Google Scholar 

  • Battaille R, Chappard D, Alexandre C, Dessauw P, Sany J (1986) Interest of bone histomor-phomeric analysis in monoclonal gammopathy. Br J Cancer 53:805–810

    Article  Google Scholar 

  • Beliel OM, Singer FR, Coburn JW (1973). Prostaglandins: effect on plasma calcium concentration. Prostaglandins 3:237–241

    Article  PubMed  CAS  Google Scholar 

  • Bertolini DR, Nedwin GE, Brown TS, Smith DD, Mundy GR (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:576–578

    Article  Google Scholar 

  • Body JJ, Dumon JC, Gilbert F, Nejai S, Fernandez G (1989) Increased production of TNF alpha in tumor-associated hypercalcaemia. J Bone Miner Res 4 (Suppl):s253 (abstract)

    Google Scholar 

  • Bon jour JP, Phillipe J, Guelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA (1988) Bone and renal components in intravenous hypercalcemia of malignancy and response to a single infusion of clodronate. Bone 9:123–130

    Article  CAS  Google Scholar 

  • Boonekamp PM, Lowik CWGM, van der Wee Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM (1987). Enhancement of the inhibitory action on the transformation of osteoclast precursors into bone resorbing cells after demethylation of the amino group. Bone Miner 2:39–42

    Google Scholar 

  • Bounameaux H, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet i:471

    Google Scholar 

  • Boyd JC, Ladenson JH (1984). Value of laboratory tests in the differential diagnosis of hypercalcaemia. Am J Med 77:863–872

    Article  PubMed  CAS  Google Scholar 

  • Brenner DE, Harvey HA, Lipton A, Demers L (1982) A study of prostaglandin E2, parathormone and response to indomethacin in patients with hypercalcemia of malignancy. Cancer 49:556–561

    Article  PubMed  CAS  Google Scholar 

  • Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CYC (1984) Hypercalcaemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med 100:1–7

    PubMed  CAS  Google Scholar 

  • Breuer RI, LeBauer J (1967). Caution in the use of phosphates in the treatment of severe hypercalcemia. J Clin Endocrinol 27:695–698

    Article  CAS  Google Scholar 

  • Bringhurst FR, Bierer BE, Godeau F, Neyhard N, Varner V, Segre GV (1986) Humoral hypercalcemia of malignancy: release of a prostaglandin-stimulating bone resorbing factor in vitro by human transitional carcinoma cells. J Clin Invest 77:456–464

    Article  PubMed  CAS  Google Scholar 

  • Brown JH, Kennedy BJ (1965). Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 272:111–118

    Article  PubMed  CAS  Google Scholar 

  • Budayr AA, Halloran BP, King JC, Diep D, Nissenson RA, Strewler GJ (1989) High levels of parathyroid hormone-like protein in milk. J Bone Miner Res 4 (Suppl):sl38 (abstr).

    Google Scholar 

  • Burtis WJ, Brady TG, Wu TL, Ersbak J, Stewart AF (1989). Rapid immunoradiometric assay (IRMA) for parathyroid hormone-like protein (PTHLP). J Bone Miner Res 4 (Suppl):s310 (abstr)

    Google Scholar 

  • Chapuy MC, Meunier PJ, Alexandre C (1980). Effects of disodium dichloromethylene diphosphon-ate on hypercalcemia produced by bone metastases. J Clin Invest 65:1243–1247

    Article  PubMed  CAS  Google Scholar 

  • Coleman RE, Rubens RD (1987) 3-amino-l, l-hydroxypropylidene bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer 56:465–469

    Article  PubMed  CAS  Google Scholar 

  • Danks JA, Ebeling PR, Hayman J, Chou ST, Moseley JM, Dunlop J, Kemp BE, Martin TJ (1988) Parathyroid hormone-related protein of cancer: immunohistochemical localisation in cancers and in normal skin. J Bone Miner Res 4:273–278

    Article  Google Scholar 

  • Davies M, Hayes ME, Mawer EB, Lumb GA (1985) Abnormal vitamin D metabolism in Hodgkin’s lymphoma. Lancet ii: 1186–1188

    Google Scholar 

  • Duff GW (1989). Peptide regulatory factors in non-malignant disease. Lancet i: 1432–1435

    Google Scholar 

  • Durie BJM, Salmon SE, Mundy GR (1981). Relation of osteoclast activating factor production to the extent of metastatic bone disease in myeloma. Br J Cancer 47:21–30

    CAS  Google Scholar 

  • Fetchick DA, Bertolini DR, Sarin PS, Weintraub ST, Mundy GR, Dunn JD (1986). Production of 1,25 dihydroxyvitamin D by human T-cell lymphotrophic 1 virus transformed lymphocytes. J Clin Invest 78:592–596

    Article  PubMed  CAS  Google Scholar 

  • Fisken RA, Heath DA, Bold AM. Hypercalcaemia -a hospital survey. OJ Med 1980;196:405–418

    Google Scholar 

  • Fleish H (1982). Bisphosphonates: mechanisms of action and clinical applications. In: Peck WA (ed) Bone and mineral research, vol 1. Amsterdam, Excerpta Medica, pp 319–357

    Google Scholar 

  • Franklin RB, Tashjian AH (1975). Intravenous infusions of prostaglandin E2 raises plasma calcium in the rat. Endocrinology 97:240–243

    Article  PubMed  CAS  Google Scholar 

  • Fried RM, Voelkel EF, Rice RH, Levine L, Gaffney EV, Tashjian AH (1989) Two squamous cell carcinomas not associated with humoral hypercalcemia produce a potent bone resorption stimulating factor which is interleukin-1 alpha. Endocrinology 125:742–751

    Article  PubMed  CAS  Google Scholar 

  • Fukomoto S, Matsumoto T, Ikeda K, et al. (1988) Clinical evaluation of calcium metabolism in adult T-cell leukaemia/lymphoma. Arch Intern Med 148:921–925

    Article  Google Scholar 

  • Fukomoto S, Matsumoto T, Yamoto H et al. (1989) Supression of serum 1,25 dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D production. Endocrinology 124:2057–2062

    Article  Google Scholar 

  • Gallacher SJ, Ralston SH, Patel U, Boyle IT (1989) Side effects of Pamidronate. Lancet ii:42–43

    Google Scholar 

  • Garrett IR, Durie BJM, Nedwin GE et al. (1987) Production of lymphotoxin -a potent bone resorbing cytokine -by cultured myeloma cells. N Engl J Med 317:526–532

    Article  PubMed  CAS  Google Scholar 

  • Goltzman D, Stewart AF, Broadus AE (1981). Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. J Clin Endocrinol Metab 53:899–904

    Article  PubMed  CAS  Google Scholar 

  • Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russell RGG (1983) An interleukin-1 like factor stimulates bone resorption in vitro. Nature 306:378–380

    Article  PubMed  CAS  Google Scholar 

  • Greaves M, Ibbotson KJ, Atkins D, Martin TJ (1980) Prostaglandins as mediators of bone resorption in renal and breast tumours. Metabolism 58:201–210

    CAS  Google Scholar 

  • Hasling C, Charles P, Mosekilde L (1987) Etidronate disodium in the management of malignancy-associated hypercalcemia. Am J Med 82 (Suppl 2A):51–54

    Article  PubMed  CAS  Google Scholar 

  • Henderson JE, Shustik C, Kremer R, Rabbani SA, Hendy GN, Goltzman D (1989) Immunoreactive parathyroid hormone-like peptide in the plasma of patients with malignancy and with hyperparathyroidism. J Bone Miner Res 4 (Suppl):s323 (abstr)

    Google Scholar 

  • Herbert LA, Lemann J, Peterson JR, Lennon EJ (1966) Studies of the mechanism by which phosphate lowers serum calcium concentration. J Clin Invest 45:1866–1894

    Google Scholar 

  • Horiuchi H, Caulfield MP, Fisher JE et al. (1987) A similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 238:1566–1568

    Article  PubMed  CAS  Google Scholar 

  • Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercal caemia. O J Med 200:473–478

    Google Scholar 

  • Hosking DJ (1983). Disequilibrium hypercalcaemia. Br Med J 286:326–327

    Article  CAS  Google Scholar 

  • Hosking DJ, Gilson D (1984) Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 211:359–369

    Google Scholar 

  • Ikeda K, Mangin M, Dreyer B et al. (1988) Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNA’s from a variety of human an animal tumors associated with hypercalcaemia of malignancy. J Clin Invest 81:2010–2014

    Article  PubMed  CAS  Google Scholar 

  • Isales C, Carcangui ML, Stewart AF (1987) Hypercalcaemia in breast cancer: a re-evaluation. Am J Med 82:1143–1147

    Article  PubMed  CAS  Google Scholar 

  • Jung A (1972) Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Ann Intern Med 29:923–930

    Google Scholar 

  • Kanis JA, Urwin GH, Gray RES et al. (1987) Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 82 (Suppl 2A):55–70

    Article  PubMed  CAS  Google Scholar 

  • Kemp BE, Moseley JM, Rodda CP et al. (1987) Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 237:1568–1570

    Article  Google Scholar 

  • Klein DC, Raisz LG (1970) Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 80:1436–1440

    Article  Google Scholar 

  • Kukreja SC, Shavin DH, Wimbiscus S, Ebeling PR, Wood WI, Martin TJ (1988) Antibodies to parathyroid hormone-related protein lower serm calcium in athymic mouse models of malignancy-associated hypercalcemia. J Clin Invest 82:1798–1802

    Article  PubMed  CAS  Google Scholar 

  • Lafferty FW (1966) Pseudohyperparathyroidism. Medicine 45:247–260

    Article  PubMed  CAS  Google Scholar 

  • Martin TJ, Suva LJ (1988) Parathyroid hormone-related protein: a novel gene product. Bailliere’s Clin Endocrinol Metab 2:1003–1029

    Article  CAS  Google Scholar 

  • McDonnell GD, Dunstan CR, Evans RA et al. (1982) Quantitative bone histology in the hypercalcaemia of malignant disease. J Clin Endocrinol Metab 55:1066–1072

    Article  CAS  Google Scholar 

  • Meredino TJ, Insogna KL, Milstone LM, Broadus AE, Stewart AF (1986). A parathyroid hormone-like protein from cultured human keratinocytes. Science 231:388–390

    Article  Google Scholar 

  • Minkin C, Fredericks RS, Porkess S et al. (1981) Bone resorption and humoral hypercalcemia of malignancy: stimulation of bone resorption in vitro by tumour extracts is inhibited by prostaglandin synthetase inhibitors. J Clin Endocrinol Metab 53:941–947

    Article  PubMed  CAS  Google Scholar 

  • Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC (1988) Single versus daily intravenous aminohydroxypropylidene bisphosphonate (APD) for the hypercalcaemia of malignancy. Br Med J 296:811–814

    Article  CAS  Google Scholar 

  • Moseley JM, Kubota M, Diefenbach-Jagger H et al. (1987) Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 84:5048–5052

    Article  PubMed  CAS  Google Scholar 

  • Motokura T, Fukomoto S, Takahashi S, Watanabe T, Matsumoto T, Igarashi T, Ogata E (1988) Expression of parathyroid hormone-related protein in a human T-cell lymphoma lymphotrophic virus type 1 infected cell. Biochem Biophys Res Comm 154:1182–1188

    Article  PubMed  CAS  Google Scholar 

  • Mudde AH, Van der Berg H, Breedveld FC, Nijweide PJ, Papapoulos SE, Bijvoet OLM (1985) Lymphoma-associated hypercalcaemia. In vitro demonstration of 1,25 dihydroxyvitamin D3 production. Calcif Tissue Int 38 (Suppl):s36 (abstr)

    Google Scholar 

  • Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN (1974) Bone resorbing activity in supernatants from lymphoid cell lines. N Engl J Med 290:867–871

    Article  PubMed  CAS  Google Scholar 

  • Mundy GR, Martin TJ (1982) Hypercalcaemia of malignancy: pathogenesis and management. Metabolism 31:1247–1277

    Article  PubMed  CAS  Google Scholar 

  • Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW, Martin TJ (1984) The hypercalcemia of cancer: clinical implications and pathogenic mechanisms. N Engl J Med 310:1718–1726

    Article  PubMed  CAS  Google Scholar 

  • Mundy GR, Ibbotson KJ, D’Souza SM (1985) Tumor products and the hypercalcemia of malignancy. J Clin Invest 76:391–394

    Article  PubMed  CAS  Google Scholar 

  • Nussbaum SR, Mallette L, Gagel R et al. (1989) Single dose treatment of hypercalcemia of malignancy with aminohydroxypropylidene bisphosphonate (APD). J Bone Miner Res 4 (Suppl):s313 (abstr)

    Google Scholar 

  • Patt LM, Houck JC (1983) Role of polypeptide growth factors in normal an abnormal growth. Kidney Int 23:603–610

    Article  PubMed  CAS  Google Scholar 

  • Percival RC, Yates AJP, Gray RES et al. (1985) Mechanisms of hypercalcaemia in carcinoma of the breast. Br Med J 291:776–779

    Article  CAS  Google Scholar 

  • Perlia CP, Gubisch NJ, Wolter J, Edelberg D, Dederick MM, Taylor SG (1970) Mithramycin treatment of hypercalcemia. Cancer 1970; 25:389–394

    Article  PubMed  CAS  Google Scholar 

  • Raisz LG, Simmons HA, Sandberg AL, Canalis E (1983). Direct stimulation of bone resorption by epidermal growth factor. Endocrinology 23:603–610

    Google Scholar 

  • Ralston SH (1987) The pathogenesis of humoral hypercalcaemia of malignancy. Lancet ii: 1443–1446

    Google Scholar 

  • Ralston SH, Fogelman I, Gardner MD, Boyle IT (1982) Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet i:903–905

    Google Scholar 

  • Ralston SH, Fogelman I, Gardner MD, Boyle IT (1984a) Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J 288:812–813

    Article  Google Scholar 

  • Ralston SH, Cowan RA, Robertson AG, Gardner MD, Boyle IT (1984b) Circulating vitamin D metabolites »and hypercalcaemia of malignancy. Acta Endocrinol 106:556–563

    PubMed  CAS  Google Scholar 

  • Ralston SH, Fogelman I, Gardner MD, Dryburgh FJ, Cowan RA, Boyle IT (1984c) Hypercalcaemia of malignancy: evidence for a non-parathyroid humoral mediator with an effect on renal tubular calcium handling. Clin Sci 66:187–191

    PubMed  CAS  Google Scholar 

  • Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT (1985) Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treat ment of cancer-associated hypercalcaemia. Lancet ii:907–910

    Google Scholar 

  • Ralston SH, Alzaid AA, Gardner MD, Boyle IT (1986) Treatment of cancer-associated hypercalcaemia with combined aminohydroxypropylidene bisphosphonate and calcitonin. Br Med J 292:1549–1550

    Article  CAS  Google Scholar 

  • Ralston SH, Cowan RA, Gardner MD, Fräser WD, Marshall E, Boyle IT (1987) Comparison of intestinal calcium absorption and circulating 1,25-dihydroxyvitamin D levels in malignancy-associated hypercalcaemia and primary hyperparathyroidism. Clin Endocrinol 26:281–291

    Article  CAS  Google Scholar 

  • Ralston SH, Alzaid AA, Gallacher SJ, Gardner MD, Cowan RA, Boyle IT (1988) Clinical experi ence with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med 258:825–834

    Google Scholar 

  • Ralston SH, Boyce BF, Cowan RA, Gardner MD, Fräser WD, Boyle IT (1989a) Contrasting mechanisms of hypercalcemia in patients with early and advanced humoral hypercalcemia of malignancy. J Bone Miner Res 4:103–111

    Article  PubMed  CAS  Google Scholar 

  • Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer associated hypercalcaemia; morbidity and mortality: experience in 126 patients. Ann Intern Med 112:499–504

    PubMed  CAS  Google Scholar 

  • Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fräser WD, Cowan RA, Boyle IT (1989b) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet ii: 1180–1183

    Google Scholar 

  • Ringerberg OS, Ritch PS (1987) Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. Clin Ther 9:1–7

    Google Scholar 

  • Robertson RB, Baylink DJ, Metz SA, Cummings KB (1976) Plasma prostaglandin E in patients with cancer with and without hypercalcaemia. J Clin Endocrinol Metab 43:1330–1335

    Article  PubMed  CAS  Google Scholar 

  • Rodan G, Insogna KL, Vignery A et al. (1983) Factors associated with humoral hypercalcaemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest 72:1151 -1515

    Article  Google Scholar 

  • Rodda CP, Kubota M, Heath JA et al. (1988) Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: Comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. J Endocrinol. 117:261–271

    Article  PubMed  CAS  Google Scholar 

  • Rosenthal N, Insognal KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF (1985) Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcaemia. J Clin Endocrinol Metab 60:29–33

    Article  PubMed  CAS  Google Scholar 

  • Sabatini M, Boyce BF, Aufdemorte T, Bonewald L, Mundy GR (1988) Infusions of recombinant interleukin-1 alpha and beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA 85:5235–5239

    Article  PubMed  CAS  Google Scholar 

  • Sato K, Fuji Y, Kasono K, Tsushima T, Shizume K (1988) Production of interleukin-1 alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the oesophagus (EC-GI) derived from a patient with hypercalcemia. J Clin Endocrinol Metab 67:592–621

    Article  PubMed  CAS  Google Scholar 

  • Sato K, Fuji Y, Kashara T et al. (1989) Treatment by anti-PTH related protein antibody and anti-interleukin-1 antibody of hypercalcemia in nude mice transplanted with squamous cell carcinoma producing PTHrP and IL-1 alpha. J Bone Miner Res 4 (Suppl):s310 (abstr)

    Google Scholar 

  • Seyberth HW, Segre GV, Morgan JL, Sweetman BJ, Potts JT, Oates JA (1975) Prostaglandins as mediators of hypercalcemia in certain types of cancer. N Engl J Med 273:1278–1283

    Article  Google Scholar 

  • Shigeno C, Yamamoto I, Dokoh S et al. (1985) Identification of l,24R-dihydroxyvitamin D3-like bone resorbing lipid in a patient with cancer-associated hypercalcemia. J Clin Endocrinol Metab 61:761–768

    Article  PubMed  CAS  Google Scholar 

  • Simpson EL, Mundy GR, D’souza SM, Ibbotson KJ, Bockman R, Jacobs JW (1983) Absence of parathyroid hormone messenger RNA in non-parathyroid tumors associated with hypercalcemia. N Engl J Med 309:325–330

    Article  PubMed  CAS  Google Scholar 

  • Skrabanek P, McPartlin D, Powell DM (1980) Tumour hypercalcaemia and ectopic hyperparathyroidism. Medicine 59:262–282

    Article  PubMed  CAS  Google Scholar 

  • Sleeboom HP, Bijvoet OLM, Van Oosteroom AT, Gleed JH, O’Riordan JLH (1983) Comparison of intravenous (3-amino-l-hydroxypropylidene)-l, 1-bisphosphonate and volume repletion in tumour induced hypercalcaemia. Lancet ii:239–243

    Google Scholar 

  • Stewart AF, Horst RL, Deftos LJ, Cadman EC, Lang R, Broadus AE (1980) Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups. N Engl J Med 303:1377–1383

    Article  PubMed  CAS  Google Scholar 

  • Stewart AF, Vignery A, Silvergate A et al. (1982) Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 55: 219–227

    Article  PubMed  CAS  Google Scholar 

  • Stewart AF, Insogna KL, Goltzman D, Broadus AE (1983) Identification of adenylate cyclase stimulating activity in extracts of tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 80:1454–1459

    Article  PubMed  CAS  Google Scholar 

  • Stewart AF, Insogna KL, Goltzman D, Broadus AE. Suva LJ, Winslow GA, Moseley JM et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalemia: cloning and expression. Science 237:893–896

    Article  Google Scholar 

  • Strewler GJ, Williams RD, Nissenson RA (1983) Human renal carcinoma cells produce hypercalcaemia in the nude mouse and a novel protein recognised by parathyroid hormone receptors. J Clin Invest 71:769–774

    Article  PubMed  CAS  Google Scholar 

  • Strewler GJ, Stern PH, Jacobs JW et al. (1987) Parathyroid hormone-like protein from renal carcinoma cells: structural and functional homology with parathyroid hormone. J Clin Invest 80:1803–1807

    Article  PubMed  CAS  Google Scholar 

  • Suki WN, Yium JJ, Von Minden M, Saller-Hebert C, Eknoyan C, Martinez-Maldonado M (1970) Acute treatment of hypercalcemia with furosemide. N Engl J Med 283:836–840

    Article  PubMed  CAS  Google Scholar 

  • Suva LJ, Winslow GA, Moseley JM et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896

    Article  PubMed  CAS  Google Scholar 

  • Tashjian AH (1975). Tumor humors and the hypercalcemia of cancer. N Engl J Med 293:1317–1318

    Article  PubMed  Google Scholar 

  • Tashjian AH, Levine L (1978). Epidermal growth factor stimulates prostaglandin production and bone resorption in cultured mouse calvariae. Biochem Biophys Res Comm 85:966–972

    Article  PubMed  CAS  Google Scholar 

  • Tashjian AH, Voelkel EH, Lazzaro M et al. (1985) Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvariae. Proc Natl Acad Sci USA 82:4535–4538

    Article  PubMed  CAS  Google Scholar 

  • Tashjian AH, Voelkel EF, Lloyd W, Derynck R, Winkler ME, Levine L (1986) Actions of growth factors on plasma calcium. J Clin Invest 78:1405–1409

    Article  PubMed  CAS  Google Scholar 

  • Thallasinos N, Joplin GF (1968) Phosphate treatment of hypercalcaemia due to carcinoma. Br Med J iv:14–19

    Article  Google Scholar 

  • Thallasinos N, Joplin GF (1970) Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet ii:537–539

    Google Scholar 

  • Thiebaud D, Jaeger PH, Jaquet AF, Burckhardt P (1986a) A single day treatment of tumour induced hypercalcaemia by intravenous aminohydroxypropylidene bisphosphonate. J Bone Miner Res 1:555–562

    Article  PubMed  CAS  Google Scholar 

  • Thiebaud D, Portmann L, Jaeger P et al. (1986b) Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy. Bone 7:247–253

    Article  PubMed  CAS  Google Scholar 

  • Tracey KJ, Vlassara H, Cerami A (1989). Cachectin/tumour necrosis factor. Lancet i: 1122–1126

    Google Scholar 

  • Travers MT, Barrett-Lee PJ, Berger U, et al. (1988) Growth factor expression in normal, benign and malignant breast tissue. Br Med J 296:1621–1624

    Article  CAS  Google Scholar 

  • Warrell RP, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS (1988) Gallium nitrate for acute treatment of cancer-related hypercalcemia. Ann Intern Med 108:669–674

    PubMed  Google Scholar 

  • Warwick OH, Yendt ER, Olin JS (1961). The clinical features of hypercalcemia associated with malignant disease. J Canad Med Ass 23:719–723

    Google Scholar 

  • Wisneski LA, Croom WP, Silva OL, Becker KL (1978) Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 24:219–222

    PubMed  CAS  Google Scholar 

  • Wo G, Bonewald LF, Oreffo R, Chirgwin JM, Capony F, Rochefort H, Mundy GR (1989) Evidence that lysosomal procathepsin D secreted by human breast cancer cells activates osteoclasts. J Bone Miner Res 5:s322 (abstr)

    Google Scholar 

  • Yamamoto I, Kitamura N, Aoki J et al. (1987) Circulating 1,25 dihydroxyvitamin D concentrations in patients with renal cell carcinoma hypercalcaemia are rarely suppressed. J Clin Endocrinol Metab 64:175–179

    Article  PubMed  CAS  Google Scholar 

  • Yamamoto I, Kawano M, Sone T, Iwato K, Shigeno C, Kuramoto A (1989) Production of interleukin-1 beta, a potent bone resorbing cytokine, by human myeloma cells. J Bone Miner Res 5:s254 (abstr)

    Google Scholar 

  • Yates AJP, Guttierez GE, Smolens P et al. (1988) Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism in vivo and in vitro. J Clin Invest 81:932–938

    Article  PubMed  CAS  Google Scholar 

  • Yonenda T, Alsina M, Chavez J, Bonewald L, Mundy GR (1989) Hypercalcemia in a human tumor is due to tumor necrosis factor production by host immune cells. J Bone Miner Res 4 (Suppl):s324 (abstr)

    Google Scholar 

  • Yoshimito K, Yamasaki R, Sakai H et al. (1989) Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinal Metab 68:976–981

    Article  Google Scholar 

Download references

Authors
  1. S. H. Ralston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Imperial Cancer Research Fund Clinical Oncology Unit, United Medical and Dental Schools of Guy’s and St Thomas’s Hospitals, Guy’s Hospital, London, SE1 9RT, UK

    R. D. Rubens BSc, MD, FRCP (Professor) (Professor)

  2. Department of Nuclear Medicine, Guy’s Hospital, London, SE1 9RT, UK

    I. Fogelman BSc, MD, FRCP (Consultant Physician) (Consultant Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag London Limited

About this chapter

Cite this chapter

Ralston, S.H. (1991). Pathogenesis and Management of Cancer-Associated Hypercalcaemia. In: Rubens, R.D., Fogelman, I. (eds) Bone Metastases. Springer, London. https://doi.org/10.1007/978-1-4471-3254-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3254-7_8

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-3256-1

  • Online ISBN: 978-1-4471-3254-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation